Cognixion is a technology company.
Cognixion has raised $12.0M across 1 funding round.
Key people at Cognixion.
Cognixion has raised $12.0M in total across 1 funding round.
Cognixion has raised $12.0M in total across 1 funding round.
Cognixion's investors include 15th Rock Ventures, Arkitekt Ventures, Fusion Fund, Harmonix Fund, Prime Movers Lab, Satori Capital, Westcott LLC.
Key people at Cognixion.
Cognixion is a neurotechnology company developing noninvasive brain-computer interfaces (BCIs) to enable communication and independence for individuals with disabilities.[1][2][3] Its flagship product, the Cognixion ONE Axon-R, is a self-contained augmented reality (AR) headset integrating EEG, AI, and visual stimuli for precise brain activity measurement, neurofeedback, and biosignal-based control of apps, smart homes, and speech output.[1][2] Targeting people with physical and neurological impairments, Cognixion solves accessibility barriers in communication and daily living, backed by Amazon and showing growth through clinical partnerships with institutions like Johns Hopkins and Mass General.[2]
Founded in 2014 (formerly Smartstones) and headquartered in Toronto, Canada, the company has filed 19 patents in electroencephalography, neurotechnology, and virtual reality, positioning it for expansion in healthcare and assistive tech.[1]
Cognixion was founded in 2014 in Toronto, Canada, initially as Smartstones, before rebranding to focus on AR and BCI.[1] Andreas Forsland, the founder and CEO, launched the company around 2015 with a patient-centered mission, differentiating it from tech-heavy rivals like Neuralink by prioritizing advocacy for disability solutions over pure technological investment.[2] The idea emerged from Forsland's vision for noninvasive tools that deliver immediate benefits, such as speech synthesis and home automation via biosignals, evolving from early assistive communication prototypes to advanced research-grade platforms.[1][2]
Early traction came through strategic backing from Amazon, integrating Alexa for smart home control, and clinical collaborations with top institutions like Johns Hopkins, Mass General, Northwell Health, and the Veterans Health Administration, validating its headset in real-world neurotech applications.[2]
Cognixion rides the surging BCI trend, projected to transform neuromedicine, assistive tech, and human augmentation amid rising demand for disability solutions and aging populations.[1][2] Its timing aligns with noninvasive tech maturation—post-2015 BCI hype—capitalizing on AI advancements and AR hardware like headsets, while market forces favor ethical, low-risk alternatives to invasive implants amid regulatory scrutiny.[2] By advocating for patients and partnering with Amazon and hospitals, Cognixion influences the ecosystem, accelerating clinical adoption, biomarker development, and inclusive neurotech, potentially bridging consumer and medical BCI markets.[1][2]
Cognixion is poised for breakthroughs in noninvasive BCI, with Axon-R expansions into consumer apps, deeper Alexa synergies, and hinted major partnerships driving commercialization.[2] Trends like AI-enhanced neurofeedback and hybrid implant-noninvasive systems will shape its path, amplifying impact in healthcare amid growing investments in accessible neurotech.[1][2] Its influence may evolve from research tool to mainstream assistive platform, redefining independence for millions—echoing its origins in patient-first innovation.
Cognixion has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $12.0M Seed | 15th Rock Ventures, Arkitekt Ventures, Fusion Fund, Harmonix Fund, Prime Movers Lab, Satori Capital, Westcott LLC |
